Eur J Heart Fail. 2026 May 29:xuag177. doi: 10.1093/ejhf/xuag177. Online ahead of print.ABSTRACTBACKGROUND: Acoramidis, an oral transthyretin stabilizer that achieves near-complete (≥90%) transthyretin stabilization, demonstrated significant clinical benefit over placebo in participants with transth
J Hum Genet. 2026 May 29. doi: 10.1038/s10038-026-01482-x. Online ahead of print.ABSTRACTGiven the increasing number of diseases for which causative genes have been identified, we are facing the need for implementing comprehensive genome sequence analysis as a molecular diagnostic system for patient
J Formos Med Assoc. 2026 May 29:S0929-6646(26)00598-X. doi: 10.1016/j.jfma.2026.05.100. Online ahead of print.ABSTRACTBACKGROUND: Primary Cutaneous Amyloidosis (PCA) is a skin-limited disorder more common in Southeast Asian. Previous studies have identified mutations located in a fibronectin type II
No abstractOphthalmol Retina. 2026 May 29:S2468-6530(26)00208-3. doi: 10.1016/j.oret.2026.05.001. Online ahead of print.NO ABSTRACTPMID:42212998 | DOI:10.1016/j.oret.2026.05.001
N Engl J Med. 2026 May 29. doi: 10.1056/NEJMoa2603870. Online ahead of print.ABSTRACTBACKGROUND: The efficacy of teclistamab, a bispecific antibody targeting B-cell maturation antigen and CD3, as early-line monotherapy in relapsed or refractory multiple myeloma is unclear.METHODS: We randomly assign
J Clin Oncol. 2026 May 29:JCO2600755. doi: 10.1200/JCO-26-00755. Online ahead of print.ABSTRACTPURPOSE: In immunoglobulin light chain (AL) amyloidosis, amyloid fibrils cause organ dysfunction. Anselamimab, a monoclonal antibody, selectively binds to amyloid fibrils, accelerating their clearance.METH
No abstractCirc Cardiovasc Imaging. 2026 May 29:e020031. doi: 10.1161/CIRCIMAGING.126.020031. Online ahead of print.NO ABSTRACTPMID:42212380 | DOI:10.1161/CIRCIMAGING.126.020031
No abstractJ Med Internet Res. 2026 May 28;28:e97621. doi: 10.2196/97621.NO ABSTRACTPMID:42207869 | DOI:10.2196/97621
No abstractJAMA Ophthalmol. 2026 May 28. doi: 10.1001/jamaophthalmol.2026.1576. Online ahead of print.NO ABSTRACTPMID:42207525 | DOI:10.1001/jamaophthalmol.2026.1576
JRSM Cardiovasc Dis. 2026 May 25;15:20480040261431376. doi: 10.1177/20480040261431376. eCollection 2026 Jan-Dec.ABSTRACTCongestion drives symptoms and adverse outcomes in heart failure (HF), and loop diuretics remain the cornerstone of decongestion. Yet randomized trials of diuretic strategies and o
EJNMMI Res. 2026 May 28. doi: 10.1186/s13550-026-01453-5. Online ahead of print.ABSTRACTBACKGROUND: Dialysis-related amyloidosis (DRA) is a recognized complication of long-term dialysis caused by progressive deposition of β2-microglobulin amyloid in osteoarticular and periarticular tissues. Although
No abstractEur J Intern Med. 2026 May 27:106975. doi: 10.1016/j.ejim.2026.106975. Online ahead of print.NO ABSTRACTPMID:42203534 | DOI:10.1016/j.ejim.2026.106975
Endocr J. 2026 May 27. doi: 10.1507/endocrj.EJ26-0079. Online ahead of print.ABSTRACTAmyloid spherule-containing prolactinomas are rare entities associated with dopamine agonist (DA) resistance and aggressive behaviour. We report a giant amyloid spherule-containing prolactinoma with a substantial tu
No abstractJ Neurol Sci. 2026 May 25;488:126021. doi: 10.1016/j.jns.2026.126021. Online ahead of print.NO ABSTRACTPMID:42202612 | DOI:10.1016/j.jns.2026.126021
Eur Stroke J. 2026 May 6;11(5):aakag052. doi: 10.1093/esj/aakag052.ABSTRACTINTRODUCTION: The most frequent causes of ICH include arteriolosclerotic small vessel disease (aSVD-ICH) and cerebral amyloid angiopathy (CAA-ICH). The predominant underlying pathology and natural history of ICH patients with
J Am Coll Cardiol. 2026 May 10:S0735-1097(26)06349-7. doi: 10.1016/j.jacc.2026.04.030. Online ahead of print.ABSTRACTBACKGROUND: Cardiac amyloidosis (CA) is a progressive infiltrative cardiomyopathy associated with conduction disease and arrhythmias, although their true burden and relationship with
Cardiol Ther. 2026 Jun;15(2):231-253. doi: 10.1007/s40119-026-00452-w. Epub 2026 May 27.ABSTRACTINTRODUCTION: Transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive disease characterized by the accumulation of misfolded transthyretin amyloid proteins in the myocardium, often leads to heart fa
Cardiol Ther. 2026 Jun;15(2):201-229. doi: 10.1007/s40119-026-00450-y. Epub 2026 May 27.ABSTRACTINTRODUCTION: Timely diagnosis and treatment are essential for improving outcomes and quality of life in patients with transthyretin (ATTR) amyloidosis. Early multisystem manifestations are often unrecogn
Clin Pharmacokinet. 2026 May 27. doi: 10.1007/s40262-026-01651-3. Online ahead of print.ABSTRACTBACKGROUND AND OBJECTIVE: We assessed the consistency of serum transthyretin (TTR) knockdown with the RNA interference therapeutic vutrisiran across subpopulations of patients with hereditary TTR amyloido
Circ Cardiovasc Imaging. 2026 May 27:e019610. doi: 10.1161/CIRCIMAGING.126.019610. Online ahead of print.ABSTRACTBACKGROUND: Cardiac amyloidosis (CA) is an underdiagnosed yet treatable cause of heart failure in which timely diagnosis is essential to initiate life-prolonging therapies. While artifici
ACG Case Rep J. 2026 May 26;13(5):e02128. doi: 10.14309/crj.0000000000002128. eCollection 2026 May.ABSTRACTHepatic amyloid light-chain (AL) amyloidosis is characterized by amyloid protein deposition in the liver, requiring biopsy for diagnosis. We report a 71-year-old man with lymphoplasmacytic lymp
J Thorac Imaging. 2026 May 27. doi: 10.1097/RTI.0000000000000878. Online ahead of print.ABSTRACTPURPOSE: To evaluate the diagnostic and prognostic utility of multi-chamber myocardial strain, and its correlation with native T1 mapping and late gadolinium enhancement (LGE) imaging, by cardiac magnetic
Sensors (Basel). 2026 May 11;26(10):3035. doi: 10.3390/s26103035.ABSTRACTWearable sensors enable continuous recording of electrocardiographic, photoplethysmographic, and inertial signals and have accelerated the development of digital biomarkers in cardiovascular medicine. Transthyretin amyloidosis
Diagnostics (Basel). 2026 May 20;16(10):1558. doi: 10.3390/diagnostics16101558.ABSTRACTBackground/Objectives: Differentiating clinically suspected cardiac amyloidosis from hypertrophic cardiomyopathy (HCM) remains a significant clinical challenge, especially when contrast-enhanced imaging is contrai
